Yes! All around the world groundbreaking research has been and is being done regarding psychedelic-therapy.
A growing number of peer-reviewed studies have investigated psychedelic-assisted psychotherapy in the context of serious conditions, including, but not limited to, treatment-resistant depression, disordered eating, post-traumatic stress disorder and end-of-life distress. These studies are conducted in controlled settings and involve careful screening, therapeutic preparation, and integration.
Some foundational studies on can be found at the following links:
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
- Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
TheraPsil is also contributing to current and future psilocybin research. Observational research studies have been designed in collaboration with researchers from McGill University, Northern Ontario School of Medicine, and the world’s first Psychedelic Research Centre at Imperial College, London. TheraPsil is a partner in a groundbreaking clinical trial, launching in 2025. Learn more here.
